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Tetrahydrobiopterin (BH4) has been recently approved 
as a treatment of patients with phenylketonuria. How-
ever, as a confirmation of BH4-responsiveness, it might 
require a very expensive trial treatment with BH4 or 
prolonged BH4-loading procedures. The selection of pa-
tients eligible for BH4-therapy by means of genotyping 
of the PAH gene mutations may be recommended as a 
complementary approach. A population-wide genotyp-
ing study was carried out in 1286 Polish phenyloketonu-
ria-patients. The aim was to estimate the BH4 demand 
and to cover prospectively the treatment by a National 
Health Fund. A total of 95 types of mutations were 
identified. Genetic variants corresponding with prob-
able BH4-responsiveness were found in 28.2% of cases. 
However, patients with mild or classical phenylketonuria 
who require continuous treatment accounted for 11.4% 
of the studied population only. Analysis of the published 
data shows similar percentage of the “BH4-responsive” 
variants of a PAH gene in patients from other countries 
of Eastern Europe. Therefore, it can be concluded, that 
the proportion of phenylketonuria-patients who could 
benefit from the use of BH4 reaches approximately 10% 
in the entire region.
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INTRODUCTION
Phenylketonuria (PKU; MIM# 261600) is the most 
common inborn error of amino acid metabolism caused 
by the mutations of the phenylalanine hydroxylase 
(PAH) gene (Bickel et al., 1981). Currently, more than 
800 mutations have been described (www.biopku.org) as 
resulting in PKU or its milder form — a mild hyper-
phenylalaninemia. PKU treatment consists in low-phe-
nylalanine diet, which, unfortunately, is not maintained 
properly by the majority of teenagers and adults who 
typically manifest serious compliance problems (Blau et 
al., 2010; Walter et al., 2002). In non-compliant persons 
severe brain dysfunction may develop (Smith et al., 1990; 
Christ et al., 2010; Bik-Multanowski et al., 2011). 
Tetrahydrobiopterin (BH4) has been proposed as a 
treatment to PKU patients (Kure et al., 1999; Muntau et 
al., 2002). It has been accepted by FDA and EMA in 
2007 and 2008, respectively. Although very expensive, 
with yearly costs reaching 100 000 Euro per an average 
adult, this therapy  significantly increases treatment ef-
ficiency and improves the quality of life. Therefore, the 
PKU community has enthusiastically greeted it. Unfor-
tunately, only selected patients respond to BH4 and 
provide clinical confirmation of the treatment effective-
ness  (demonstrable increase in the permissible protein 
intake). Several weeks of an expensive trial-treatment is 
also often required. Therefore, preselection of BH4-non-
responders by means of genotyping of the PAH gene 
mutations (Blau & Erlandsen, 2004) should be recom-
mended to avoid unnecessary (and expensive) BH4-chal-
lenge in persons with definitively “BH4-resistant” geno-
types. 
In the present study, a population-wide genotyping 
was carried out in Polish PKU-patients aiming at esti-
mating  the number of potential BH4-responders and 
the BH4 demand, as well as financing it prospectively 
by a National Health Fund.
PATIENTS AND METHODS
Starting from 2007, all Polish patients with PKU were 
offered genotyping for mutations of the PAH gene. Pa-
tients were informed about possibility of genetic testing 
in their regional PKU treatment centers as well as dur-
ing meetings for PKU families and using web pages of 
patient organizations. Prior to genotyping, all patients in-
terested in this procedure were asked to sign appropriate 
informed consent form approved by the Ethics Commit-
tee.
Blood samples obtained from the patients were sent 
to the Chair of Pediatrics in Krakow, where genetic 
testing was performed. DNA was extracted from the 
leukocytes with the use of standard methods. Screening 
of all exons and  flanking intronic regions of the PAH 
gene with the use of DHPLC method (WAVE system, 
*e-mail: AgMir@mp.pl
Abbreviations: PKU, phenylketonuria; BH4, tetrahydrobiopterin; 
PAH, phenylalanine hydroxylase; DHPLC, denaturing high-perfor-
mance liquid chromatography; MLPA, multiplex ligation-depend-
ent probe amplification
Vol. 60, No 4/2013
613–616
on-line at: www.actabp.pl
614           2013M. Bik-Multanowski and others
Transgenomics) was used to select the samples con-
taining potential gene variants. Subsequent sequencing 
(3130 Genetic Analyzer, Applied Biosystems) allowed 
to diagnose the specific point mutations. To detect 
the exon deletions MLPA technique (SALSA MLPA 
kit P055 PAH, MRC-Holland) was used followed by 
PCR-based detection methods as described earlier (Bik-
Multanowski & Pietrzyk, 2008)  In case of the new de-
letions microarray-based mapping (Cytogenetics 2.7M 
Array, Affymetrix) and final sequencing of the regions 
flanking the deletion (technical details on request) were 
used. When the above procedure didn’t allow to detect 
both mutations, sequencing of all exons of the PAH 
gene was performed in a given sample.
Assessment of BH4-responsiveness-status of the de-
tected mutations was performed. It was based on pre-
viously published observational data — the results of 
BH4 loading test in patients selected with regard to their 
genotype (Blau & Erlandsen, 2004; Zurflüh et al., 2008; 
BIOPKU). The status of the mutations was defined as: 
— “Absent/Unlikely” (including common vari-
ants p.R158Q (c.473G>A) and IVS10-
11G>C (c.1066-11G>A) for which only sin-
gle cases of BH4-responsiveness were reported), 
— “Probable” (convincing data reported on BH4-
responsiveness in carriers of the given mutation) and 
—“Undefined” (no data available relating to 
the given genetic variant). 
New, previously not described nonsense 
mutations and large deletions were assumed 
as “non-responsive” as well as frameshift 
variants and splice site mutations (with the 
exception of variants previously reported 
and corresponding with the milder types of 
hyperphenylalaninemia). The clinical severity 
of hyperphenylalaninemia was assessed on 
the base of the medical records analysis and 
the genotyped patients. 
RESULTS
A total of 1286 PKU-patients (approx. 
70% of the entire population of registered 
Polish patients) were genotyped. Genotyp-
ing allowed to identify 95 types of muta-
tions including nine genetic variants not 
described previously. Mutations were identi-
fied in 96.9% of the alleles. The most preva-
lent mutation p.R408W (c.1222C>T) was 
detected in 1590 alleles (61.8%). In next 
534 alleles (20.8%) one of ten genetic vari-
ants was found, revealing allelic frequency 
above 1%: IVS10-11G>A (c.1066-11G>A), 
p.R158Q (c.473G>A), p.P281L (c.842C>T), 
IVS12+1G>A (c.1315+1G>A), p.A300S 
(c.898G>T), p.A403V (c.1208C>T), 
p.R261Q (c.782G>A), p.Y414C 
(c.1241A>G), p.I306V (c.916A>G), 
p.R252W (c.754C>T). The remaining 84 
mutation types were rare variants with allelic 
frequency below 1% or some private muta-
tions.
In 2068 alleles, 44 types of mutations de-
termining absent or unlikely BH4-respon-
siveness were found, whereas in 384 alleles 
31 types of “BH4-responsive” were present 
and in 39 alleles 20 types of mutations with 
undefined BH4-status were detected. In 81 
patients only one mutation was recognized 
(3.1% of alleles).
To select a group of potential BH4-responders, analy-
sis of 1223 cases was performed. It included 1205 per-
sons with both mutations and 18 persons with only one 
identified mutation which was not a non-responsive one. 
The remaining 63 patients were not analyzed. 
BH4-responsiveness was excluded in 64.2% of the 
studied population (825 patients), in whom two muta-
tions, definitely or most probably non-responsive were 
identified. Positive response to BH4 was expected in 
28.2% of cases (363 patients) in whom at least one 
“BH4-responsive” mutation was found. 
The majority of probable BH4-responders (216 
patients; 16.8% of cases) carried PAH gene muta-
tions which were theoretically corresponding with 
the presence of a mild hyperphenylalaninemia (such 
as p.A403V, p.I306V, p.A300S and p.R297H). As 
expected, in most patients from this group, medical 
records analysis revealed blood phenylalanine concen-
trations constantly below 0.6 mmol/l (typical for mild 
hyperphenylalaninemia). In some cases, higher con-
centrations (typical for mild PKU) were recorded in 
the neonatal screening and incidentally in case of high 
dietary protein intake or a fever caused by an acute 
infection. However, as the majority of blood phenyla-
Table 1. Common genotypes with regard to the BH4-responsiveness
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lanine concentrations remained below of 0.6 mmol/l, 
such borderline-phenotype patients were regarded as 
having mild hyperphenylalaninemia. 
The remaining potential BH4-responders (147 pa-
tients; approximately 11.4% of all cases genotyped in our 
survey) were patients with mild or classical PKU. The 
mutations: p.R261Q, p.Y414C, p.L348V and p.V388M 
were the most prevalent genetic variants detected in 
nearly ¾ of the alleles in this group. 
In 2.7% of patients (35 cases) at least one mutation 
was found with an undefined BH4-status. Based on the 
genotyping of the PAH gene mutations, the BH4-re-
sponse could not be predicted. 
The most common genotypes identified in the studied 
population are listed in Table 1. Details on the detected 
genetic variants can be found in the Supplementary Ta-
ble 1 and Table 2 at www.actabp.pl. 
DISCUSSION
To our knowledge, the present study has been the 
largest national PAH gene mutation analysis published 
until now. We intended to test the largest possible group 
of patients with classical and milder forms of PKU. 
Adults with this disease often relax or sometimes even 
abandon their diet. They also miss scheduled control 
visits in their outpatient clinics. These are especially pa-
tients with mild disease course. Therefore, the group of 
adult patients with mild phenylketonuria and mild hyper-
phenylalaninemia caused by potentially BH4-responsive 
mutations of the PAH gene might be slightly unrepre-
sentative in our material. On the other hand, vast major-
ity of the genotyped patients were diagnosed after intro-
ducing a neonatal screening in all regions of the country 
(PKU screening did not cover the entire population be-
fore 1987). Virtually, all of these persons were registered 
in PKU treatment clinics and were offered genotyping 
regardless of their disease severity. Therefore, our data 
seems to be representative for the whole Polish PKU 
population.
It seems interesting that previous reports stressed 
low percentage of “BH4-responsive” mutations in 
Polish population (Zurflüh et al., 2008; Zschocke, 
2003). This appears to be not appropiate in relation to 
our data. The reason for this discrepancy was prob-
ably a low number of patients with PKU who were 
genotyped and, on the other hand, a selective geno-
typing which was performed to detect the most com-
mon mutations only. In fact, when analyzing the pub-
lished data on prevalence of “BH4-responsive” vari-
ants (Zschocke, 2003), their actual percentage in Po-
land resembles the one in other countries of Eastern 
Europe, including Czech Republic, Slovakia, Bulgaria, 
Lithuania as well as, probably, Ukraine and the Euro-
pean part of Russia, where only screening for specific 
mutations was performed (Zschocke, 2003; Kozak et 
al., 1997; Kadasi et al., 1995; Kalaydjieva, 1993; Kas-
nauskiene, 2003; Nechiporenko & Lalivshits, 2000; 
Baranovskaya et al., 1996; Charikova, 1993). All these 
countries represent together a population of approx. 
200.000.000 of Europeans. Some conclusions on the 
prevalence of BH4-responsiveness in Poland may 
probably be extrapolated into the population of the 
entire region of Eastern Europe.
Although BH4-responsiveness is probable in nearly 
30% of Polish patients with hyperphenylalaninemia, 
no dietary treatment is needed to the part of them. In 
particular, in persons with mild hyperphenylalanine-
mia, in whom blood phenylalanine concentration does 
not exceed 0.6 mmol/l, no treatment is recommended 
in the majority of European countries except pregnant 
women and young children. On the other hand, the 
blood phenylalanine concentration even in patients 
with mild hyperphenylalaninemia can exceed the level 
of 0.6 mmol/l in case of incidental excessive protein 
intake. Such situation may occur in off-diet patients 
due to their irregular eating habits (as typically ob-
served among adolescents and young adults). There-
fore, it seems to be important that these patients re-
main under clinical control, to increase their safety 
level. However, the need for continuous BH4-therapy 
as preventive treatment to avoid episodes of signifi-
cant hyperphenylalaninemia (and the effectiveness of 
such therapy in the light of high residual PAH activity 
as well as typically poor treatment adherence) seems 
to be questionable. Consequently, high costs of BH4-
treatment should be individually balanced against its 
beneficial effects in each patient with mild hyperphe-
nylalaninemia.
When we exclude patients with mild hyperphenyla-
laninemia the usage of BH4 seems to be useful only in 
approximately 10% of the studied population – mostly 
in patients with mild PKU. However, patients with 
theoretically BH4-responsive genotype do not always 
respond to the BH4-treatment (Zurflüh et al., 2008). 
This situation may be caused by several reasons such 
as modifying effect of neighborhood-genes, presence 
of additional genetic variants enhancing or inhibiting 
exon splicing or direct interaction of two given types 
of mutated PAH proteins in compound heterozy-
gotes. Bearing in mind the fact, that around 50% of 
carriers of the p.R261Q mutation (the most common 
BH4-response-related genetic variant in the group of 
our classical/mild-PKU patients) as well as 10–20% 
of mild-PKU patients carrying other BH4-responsive 
mutations do not respond to BH4 (BIOPKUdb), it 
may be assumed that the rate of BH4-responders who 
require a BH4-treatment, reaches approx. 8–10% in 
the Polish population of PKU patients. To ultimately 
select the BH4-responders, BH4-loading procedure 
and/or trial treatment should be proposed to these 
patients. It allows a precise assessment of the expect-
ed increase in their dietary phenylalanine tolerance in 
relation to the BH4 therapy.
Several previous studies reported problems with 
detection of the PAH gene mutation in 2–3% of al-
leles while genotyping patients with PKU (Aulehla-
Scholz & Heilbronner, 2003; Bercovich et al., 2008; 
Cali et al., 2010). In those patients different factors, 
such as presence of functional genetic variants located 
in a deep intronic sequences or epigenetic influences 
could affect the PAH gene function. Our results are 
cohesive with these findings. In 81 patients only one 
mutation was identified. In this group, an assessment 
of the potential BH4-responsiveness was not possible 
due to 63 cases in whom only one, BH4-unresponsive 
mutation was found. Despite sequencing of all exons 
of the PAH gene knowledge on the second mutation 
remained unknown in these persons. Therefore BH4-
loading test/trial treatment wuold be necessary to se-
lect the BH4-responders.
In conclusion, approximately 8–10% of Polish patients 
with hyperphenylalaninemia may possibly benefit from 
the BH4 treatment. This percentage seems to be similar 
with other countries of Eastern Europe, inhabited by a 
population of approx. 200 000 000 citizens.
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